Cures Within Reach's AI Validation Trials
Request for Proposals (RFP) Overview

Cures Within Reach (CWR) leverages the speed, safety and cost-effectiveness of medical repurposing: testing already approved therapies for unsolved diseases. CWR focuses on proof of concept (POC) clinical trials that, if successful, catalyze follow-on funding to build the clinical evidence required for regulatory approval or for off-label use. CWR is institution-agnostic, geography-agnostic and disease-agnostic, allowing its neutral selection process to de-risk treatment options while building the pipeline for follow-on funders. For nearly 20 years, CWR's funding of over $10 million to more than 145 repurposing trials has helped to catalyze over $128 million in follow-on funding. In 2024 alone, CWR-funded research(ers) raised over $29 million in follow-on funding for trials.

In Spring 2025, CWR will launch a **Request for Proposals (RFP) to fund investigator-initiated, POC, Phase I or Phase IIA clinical trials to validate artificial intelligence (AI)-driven drug-disease matches, where the therapies identified are already approved.**

Brief Letter of Intent (LOI) submissions will be due in late Summer 2025, and top rated LOIs will be invited to submit a full proposal as part of CWR's 2-stage submission process.

Through this RFP, CWR expects to fund at least **6 clinical repurposing trials** validating AI drug-disease matches. CWR encourages all interested PIs to **start working with AI models / collaborators to build or enhance the preclinical data** needed for a successful submission. If you have an AI model, CWR encourages you to **find clinical collaborators to validate any repurposed drug-disease matches identified** by your model.

Important details/eligibility criteria about this RFP include:

- Submissions **must use an AI model** to generate a repurposing hypothesis and/or preclinical data on which the proposed clinical trial will be based.
    - Example AI models include, but are not limited to, Harvard's TxGNN, Broad Drug Repurposing Hub, Scripps' ReFRAME, Helsinki's RepurposeDrugs.org, etc.
- **POC, Phase I or Phase IIA** clinical repurposing trials in any disease area.
- Proposed trials must repurpose **already approved drugs, biologics and/or eligible cellular/gene therapies** in a disease other than the approved indication or an indication already used widely in clinical practice.
    - While both on- and off-patent therapies are eligible, CWR has a preference for off-patent.
- **Budgets of up to $100,000**, including a required 10% institutional match.
    - Additional funding will be available alongside the clinical trial budget for engaging community-based organizations to support better inclusion of underrepresented communities and patients before trial enrollment, during the study and to support post-trial dissemination of results.
- Submissions from **anywhere in the world, and PIs at any career stage** can apply. There is **no limit to the number of submissions** from any institution or PI.
- More details will be included in the full RFP, coming in Spring 2025.

Want to be added to CWR's email list for more info about the RFP? Email CJ Wright, PharmD at cj@cureswithinreach.org

Have specific questions about the RFP? Email Clare Thibodeaux, PhD at clare@cureswithinreach.org